COGT Cogent Biosciences Inc

Price (delayed)

$15.76

Market cap

$1.04B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.49

Enterprise value

$737.6M

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed ...

Highlights
The company's equity has surged by 70% QoQ and by 50% YoY
The EPS has soared by 83% YoY but it fell by 13% QoQ
Cogent Biosciences's quick ratio has decreased by 26% YoY but it has increased by 10% from the previous quarter
The gross profit has dropped by 100% year-on-year
The revenue has shrunk by 100% YoY

Key stats

What are the main financial stats of COGT
Market
Shares outstanding
65.76M
Market cap
$1.04B
Enterprise value
$737.6M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.26
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$109.56M
EBITDA
-$108.21M
Free cash flow
-$92.86M
Per share
EPS
-$2.49
Free cash flow per share
-$1.88
Book value per share
$6.97
Revenue per share
$0
TBVPS
$7.41
Balance sheet
Total assets
$366.05M
Total liabilities
$46.67M
Debt
$28.07M
Equity
$319.39M
Working capital
$303.02M
Liquidity
Debt to equity
0.09
Current ratio
11.96
Quick ratio
11.82
Net debt/EBITDA
2.76
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-42.9%
Return on equity
-47.7%
Return on invested capital
-1,241.2%
Return on capital employed
-32.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

COGT stock price

How has the Cogent Biosciences stock price performed over time
Intraday
11.3%
1 week
14.12%
1 month
47.15%
1 year
89.2%
YTD
83.68%
QTD
74.72%

Financial performance

How have Cogent Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$112.73M
Net income
-$109.56M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
The revenue has shrunk by 100% YoY
The company's net income fell by 22% YoY and by 20% QoQ
COGT's operating income is down by 20% since the previous quarter and by 14% year-on-year

Growth

What is Cogent Biosciences's growth rate over time

Valuation

What is Cogent Biosciences stock price valuation
P/E
N/A
P/B
2.26
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 83% YoY but it fell by 13% QoQ
The company's equity has surged by 70% QoQ and by 50% YoY
The P/B is 27% above the last 4 quarters average of 1.6 and 7% above the 5-year quarterly average of 1.9
The revenue has shrunk by 100% YoY

Efficiency

How efficient is Cogent Biosciences business performance
The company's return on equity has surged by 60% YoY but it fell by 6% QoQ
The ROA has soared by 53% YoY but it has contracted by 3.9% from the previous quarter

Dividends

What is COGT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COGT.

Financial health

How did Cogent Biosciences financials performed over time
The total liabilities has surged by 197% year-on-year and by 146% since the previous quarter
Cogent Biosciences's total assets has surged by 77% QoQ and by 60% YoY
The company's debt is 91% lower than its equity
The company's equity has surged by 70% QoQ and by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.